Processing

Please wait...

Settings

Settings

1. WO2014043223 - IRHOM2 INHIBITION FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

Publication Number WO/2014/043223
Publication Date 20.03.2014
International Application No. PCT/US2013/059246
International Filing Date 11.09.2013
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
C07K 16/18 (2006.01)
A61K 39/395 (2006.01)
A61P 37/00 (2006.01)
CPC
C07K 16/18
C07K 16/2896
C12Q 1/37
C12Q 1/6876
C12Q 2600/136
C12Q 2600/158
Applicants
  • HOSPITAL FOR SPECIAL SURGERY [US/US]; 535 East 70th Street New York, NY 10021, US
  • UNIVERSITY HEALTH NETWORK [CA/CA]; 190 Elizabeth Street R. Fraser Elliott Building - Room 1s-417 Toronto, ON M5G 2C4, CA
Inventors
  • ISSUREE, Priya; US
  • MARETZKY, Thorsten; US
  • MCILWAIN, David, Robert; CA
  • MAK, Tak, Wah; CA
  • BLOBEL, Carl; US
  • SALMON, Jane; US
Agents
  • DAVIS, Steven, G.; McCarter & English LLP 265 Franklin Street Boston, MA 02110, US
Priority Data
61/699,58011.09.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IRHOM2 INHIBITION FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS
(FR) INHIBITION DE IRHOM2 DANS LE TRAITEMENT DES TROUBLES INDUITS PAR UN COMPLÉMENT
Abstract
(EN)
Disclosed are methods for treating a subject with a Complement mediated (e.g., C5a mediated) disease or an immune complex mediated disease. The method comprises the step of administering to the subject an effective amount of an agent that decreases the biological activity of iRhom2 or an agent that modulates formation of a complex between iRhom2 and TACE. Also disclosed are assays for identifying such agents.
(FR)
L'invention concerne des méthodes de traitement d'une maladie induite par un complément (induite par C5a, par exemple) ou d'une maladie induite par un complexe immun. La méthode selon l'invention consiste à administrer au patient une quantité efficace d'un agent diminuant l'activité biologique de iRhom2 ou d'un agent modulant la formation d'un complexe entre iRhom2 et TACE. L'invention concerne également des dosages permettant d'identifier ces agents.
Also published as
Latest bibliographic data on file with the International Bureau